AstraZeneca and Aspen Group have inked a new partnership

By Catherine Sturman
Operating in over 100 countries, global pharmaceutical company AstraZeneca has signed an agreement with Aspen Group international (AGI) surrounding its...

Operating in over 100 countries, global pharmaceutical company AstraZeneca has signed an agreement with Aspen Group international (AGI) surrounding its residual rights to a number of its anaesthetic medicines. These medicines include Dipravan, EMLA, Xylocaine/Xylocard/Xylopract, Marcaine, Naropin, Carbpcaine and Citane.

The agreement will see the medicines enter markets outside of the US, with AGI gaining the remaining rights to AstraZeneca’s intellectual property and manufacturing expertise surrounding the anaesthetics. In addition, the company will pay over $200 million from 2017 to 2019 in performance related milestones based on sales surrounding the use of these products.

AstraZeneca will continue to manufacture and supply the medicines to AGI through a five-year transition.

Related stories

Mark Mallon, Executive Vice President, Global Product and Portfolio Strategy, AstraZeneca said: “AGI has shown that it is in a strong position to maximise the value and reach of the anaesthetic medicines through its extensive commercial network.

Disposing the remaining rights to the medicines allows both companies to benefit from greater efficiencies as AstraZeneca continues to focus our resources on our three main therapy areas.”

Under the terms of a prior agreement, AGI made an upfront payment to AstraZeneca of $520 million and agreed to make future Product Sales-related payments of up to $250 million (see first payment below), as well as paying double-digit percentage royalties on Product Sales.

AstraZeneca agreed to continue to manufacture and supply the medicines to AGI on a cost-plus basis for an initial period of 10 years.

The company has been selling off a large number of its intellectual rights surrounding the manufacture of a number of drugs, such as beta-blocker Toprol-XL, in order to further restructure its operations and resources, and implement a strategy with specific areas of focus.

With this in mind, the company is also selling its rights outside Japan to migraine drug, Zomig, to Germany’s Gruenthal, the company has previously reported.

Share

Featured Articles

Siemens: smart finance to help medical technology growth

Penny Pinnock, Business Development Manager at Siemens Financial Services UK, discusses how adopting digital technology can support the healthcare sector

Healthcare Digital news roundup: prostate cancer & AI

This week in Healthcare Digital, we heard from experts in the sector: Trevor Dearing from Illumio, Avenda Health’s Brit Berry-Pusey & Vish Charan of Abbott

Lexica shares post-COVID-19 digital healthcare trends

Joanna Smith, Digital Advisory Lead at consulting company Lexica, explores the impact of COVID-19 on digital healthcare & what role health data can play

Medical devices expanding senior healthcare innovation

Medical Devices & Pharma

Abbott’s CRM medical devices can help cardiac arrhythmia

Medical Devices & Pharma

AutoRABIT CEO Meredith Bell on DevOps strategy in healthcare

Hospitals